Aaron Wealth Advisors LLC Increases Stake in Abbott Laboratories $ABT

Aaron Wealth Advisors LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 33.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,447 shares of the healthcare product maker’s stock after purchasing an additional 7,380 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $3,689,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Carr Financial Group Corp raised its position in Abbott Laboratories by 2.0% during the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after buying an additional 76 shares during the last quarter. Gemmer Asset Management LLC raised its position in Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after buying an additional 78 shares during the last quarter. Global Financial Private Client LLC raised its position in Abbott Laboratories by 3.3% during the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after buying an additional 79 shares during the last quarter. Citizens & Northern Corp raised its position in Abbott Laboratories by 0.4% during the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after buying an additional 79 shares during the last quarter. Finally, American National Bank of Texas raised its position in Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after buying an additional 79 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 in the last ninety days. Company insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Leerink Partners reduced their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Argus reduced their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Citigroup reduced their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. BTIG Research reduced their price target on shares of Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Finally, Royal Bank Of Canada dropped their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $135.68.

Abbott Laboratories Price Performance

NYSE:ABT opened at $102.30 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a market cap of $178.16 billion, a price-to-earnings ratio of 27.50, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79. The company has a 50 day moving average price of $109.35 and a 200-day moving average price of $120.71. Abbott Laboratories has a 1-year low of $100.88 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.